The number of sessions will vary depending on the size and location of the area being treated
And then, this is a common question, is when can I or can I even stop this medication eventually
Montero A, Sparks G, Presiado M, Hamel L.: KFF health tracking poll may 2024: the publics use and views of GLP-1 drugs

Likewise, energy metabolism and appetite regulation could be altered in a therapeutic direction ( The rationale for dual-receptor agonists for GLP-1 and GIP In healthy volunteers, infusions of GLP-1 and GIP had additive effects on the stimulation of insulin secretion ( In vitro receptor binding studies explored structural requirements for GLP-1 and GLP-1/GIP chimeric peptides regarding their affinity towards the GLP-1 receptor in insulinoma cell lines ( Figure 1 gives an overview of the physiological actions of GLP-1 and GIP on various organ systems ( Table 1 ( Figure 1 Table 1 Effects of GIP receptor agonism or antagonism on glycemic control, body weight, and energy balance in animal models of obesity and diabetes (modified according to Campbell and Nauck) ( Prevention of diet-induced obesity: healthy, nonobese animals at baseline receiving experimental treatment while receiving a high-fat diet
Third, animal and in vitro models cannot be directly generalized